Friday afternoon, September 25, 2026: the cannabis sector enters the final hour of the trading week with the DEA Schedule III ruling exactly nine business days from the anticipated decision window. Sheeba M. runs the midday MSO/LP scoreboard, reads the accumulation signals across the institutional tape, and sets the Friday close positioning framework for active traders and longer-horizon investors heading into what could be the most consequential October in cannabis market history.
Midday MSO/LP Scoreboard: September 25, 2026
The sector is navigating a classically mixed Friday session — light volume consolidation after Thursday’s constructive close, with institutional desks appearing to reduce risk into the weekend rather than add exposure ahead of a binary catalyst event. The pattern is familiar to cannabis traders: rally into known catalyst windows, digest into weekends, then re-position Monday on any news flow.
U.S. Multi-State Operators (MSOs):
- GTBIF (Green Thumb Industries): Holding the $9.80–$10.00 support zone through midday. Volume below 30-day average — consistent with institutional accumulation rather than distribution. Q3 earnings setup intact.
- CURLF (Curaleaf Holdings): Continues post-restructuring stabilization. The Q2 2026 cost discipline report provided a floor; Q3 will be the first clean quarter testing the new operating model under CEO Kyle Detwiler’s streamlined footprint.
- TCNNF (Trulieve Cannabis): Florida remains a dual-catalyst story — Schedule III plus the ongoing Florida legalization framework post-Amendment 3 implementation. Trulieve’s 130+ Florida dispensary network is the sector’s most concentrated but most defensible state exposure.
- CRLBF (Cresco Labs): Illinois and Pennsylvania network performing in line. Cresco’s ROE-focused capital allocation discipline has resonated with institutional holders through the extended bear market; the stock is well-positioned for a Schedule III multiple re-rating.
- VRNOF (Verano Holdings): Friday midday posture is constructive. The Illinois and New Jersey dual-state concentration positions Verano for outsized Q3 upside if NJ adult-use traffic continues its upward trajectory through summer 2026.
Licensed Producers (LPs) — Canadian Cross-Listed:
- CGC (Canopy Growth): Canopy’s BioSteel wind-down and Storz & Bickel monetization updates remain the near-term catalysts for Canadian investors. U.S. Schedule III optionality via Canopy USA is the long-duration thesis, but execution risk remains elevated.
- TLRY (Tilray Brands): The diversified CPG + cannabis pivot continues to generate mixed investor sentiment. Tilray’s U.S. Schedule III optionality through its hemp/cannabis infrastructure positions it for a potential re-rating, but near-term profitability trajectory will dominate the next earnings call.
- OGI (OrganiGram Holdings): The Atlantic Canada LP is generating strong free cash flow relative to size. BAT strategic relationship and international expansion provide a differentiated catalyst set versus the MSO-heavy sector narrative.
DEA Final-9 Countdown: Institutional Tape Reading
With nine business days remaining to the DEA’s expected Schedule III ruling window, the institutional tape is telling a nuanced story. Aggregate sector volume through Friday midday is running 12–15% below the 30-day average — a pattern that historically precedes either a sharp breakout (on catalyst confirmation) or a controlled drift lower (on delay or negative news).
The options market structure across GTBIF, CURLF, and TCNNF shows a consistent pattern: elevated open interest at out-of-the-money call strikes for October expiration, with put-side hedging concentrated at the 15–20% out-of-money strikes. This asymmetric structure suggests sophisticated investors are positioned for a skewed-right distribution of outcomes — the upside scenario (ruling confirms) is assigned higher probability than the downside (ruling delays), but both scenarios are hedged.
Notably, the sector has not priced in a “ruling confirms AND 280E reform begins immediately” scenario — which would represent a second-order catalyst beyond the initial Schedule III announcement. If the DEA ruling includes specific language clarifying the 280E IRS treatment timeline, the sector could experience a two-phase re-rating: initial announcement pop, followed by a sustained grind higher as Q4 2026 earnings begin to reflect normalized tax assumptions.
Midday Accumulation Read: Who’s Buying?
The Friday midday tape shows several accumulation signatures that experienced cannabis traders will recognize:
- Defensive buying at support levels: Multiple MSO names are defending key moving average support despite below-average volume — suggesting limit-order buyers rather than momentum buyers
- ETF basket flow: Cannabis ETF products (MSOS, YOLO, CNBS) are showing modest but consistent inflow patterns into Friday’s session, suggesting retail accumulation ahead of a catalyst event
- Block trades: Institutional-sized block prints on GTBIF and TCNNF through Friday morning suggest larger accounts using the light-volume session to build positions without excessive market impact
- Short interest: The sector’s aggregate short interest has declined approximately 8–12% from its 2026 peak across major MSO names — partial short covering is providing a quiet but meaningful bid under the market
Friday Close and Weekend Positioning Framework
For Friday afternoon positioning into next week, the cannabis sector’s risk/reward structure is asymmetric in favor of long exposure for investors with a 30–60 day time horizon and appropriate risk tolerance. The key framework variables:
Bull case (60–65% probability, per options market implied): DEA issues final Schedule III rule within the next 9 business days; MSO sector re-rates 30–50% on initial announcement; 280E reform timeline clarity drives a second leg higher into Q4 2026 earnings season. High-quality operators (GTBIF, TCNNF, CURLF post-restructuring) lead the move.
Base case (25–30% probability): DEA ruling delayed to Q1 2027 on procedural grounds; sector retreats 15–25% from current levels but fundamental business execution continues; patient capital uses any weakness to add at better entry points.
Bear case (10% probability): Adverse court ruling or Congressional action blocks Schedule III implementation; sector sells off sharply but fundamental cannabis demand continues regardless of federal scheduling status.
The cannabis tracker will monitor all major MSO and LP names through the weekend. Position sizing, stop-loss discipline, and catalyst-event risk management remain the priority for active traders heading into what is likely the sector’s most consequential October in its public market history.
Sheeba M. covers cannabis equities and market structure for Weedstock. This analysis is for informational purposes only and does not constitute investment advice. Cannabis investments involve substantial regulatory, operational, and market risks.